TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06686030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 low dose
Description: 10mg/kg, Q3W, ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 low dose
Description: 10mg/kg, Q3W, ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: bid, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: bid, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: bid, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 high dose
Description: 20mg/kg, Q3W, ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 high dose
Description: 20mg/kg, Q3W, ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 high dose
Description: 20mg/kg, Q3W, ivgtt
Study: NCT05476848

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA test for Cytokines
Description: ELISA tests specific for cytokines (IL-1, IL-6, IL-10) and immunoglobulins (IgA, IgG, IgM) will be performed by a biochemistry lab, both for blood samples and oral swap samples.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ELISA test for Cytokines
Description: ELISA tests specific for cytokines (IL-1, IL-6, IL-10) and immunoglobulins (IgA, IgG, IgM) will be performed by a biochemistry lab, both for blood samples and oral swap samples.
Study: NCT04810858

Intervention type: OTHER
Group type: OTHER
Intervention: Multimodal, multi-parametric MRI
Description: The investigators will use multimodal, multi-parametric sequences to investigate neuroinflammatory and neurodegenerative processes in vivo. Participants will be assessed three times over 2 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Multimodal, multi-parametric MRI
Description: The investigators will use multimodal, multi-parametric sequences to investigate neuroinflammatory and neurodegenerative processes in vivo. Participants will be assessed three times over 2 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Multimodal, multi-parametric MRI
Description: The investigators will use multimodal, multi-parametric sequences to investigate neuroinflammatory and neurodegenerative processes in vivo. Participants will be assessed three times over 2 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Multimodal, multi-parametric MRI
Description: The investigators will use multimodal, multi-parametric sequences to investigate neuroinflammatory and neurodegenerative processes in vivo. Participants will be assessed three times over 2 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Immune and cytokine profiling
Description: Blood samples will be collected for immune and cytokine profiling. Participants will be assessed three times over 2 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Immune and cytokine profiling
Description: Blood samples will be collected for immune and cytokine profiling. Participants will be assessed three times over 2 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Immune and cytokine profiling
Description: Blood samples will be collected for immune and cytokine profiling. Participants will be assessed three times over 2 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Immune and cytokine profiling
Description: Blood samples will be collected for immune and cytokine profiling. Participants will be assessed three times over 2 years.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological testing
Description: Participants will have neuropsychological testing three times over 2 years.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological testing
Description: Participants will have neuropsychological testing three times over 2 years.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological testing
Description: Participants will have neuropsychological testing three times over 2 years.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological testing
Description: Participants will have neuropsychological testing three times over 2 years.
Study: NCT05833945

Intervention type: DEVICE
Intervention: Large Vessel Occlusion Biomarkers Test
Description: Duplex Point of Care test to measure the concentration of biomarkers associated to Large Vessel Occlusion in blood samples used in combination with an APP.
Study: NCT06268730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SinuSonic
Description: The SinuSonic is a commercially available, over-the-counter, self-applied nasal device designed to enhance physical well-being by reducing nasal congestion via simultaneous administration of acoustic vibration and gentle oscillating expiratory pressure.
Study: NCT05956392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen-use reduction + Sleep extension
Description: 60 minutes of a participants' daily screen-use time on school days will be repurposed for more sleep time.
Study: NCT05837247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game-based telerehabilitation exercises
Description: online Game-based home exercises are physiotherapy programs that include exercises transformed into game activities to increase the child's participation in the rehabilitation process. The exercises were planned such as; the dwarf camel game as squat exercises; the flamingo balance game as single leg balance exercises and weight-bearing activities etc. The exercise program will be conducted for 6 weeks and 3 sessions in a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises
Description: The physiotherapist will evaluate the control group patients and monitor them using only a home exercise program.
Study: NCT04825587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.
Description: By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.
Description: By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.
Study: NCT05040542

Intervention type: OTHER
Intervention: maternal exposure during pregnancy
Description: maternal exposure during pregnancy (e.g., environmental exposures and maternal inflammatory states)
Study: NCT06159127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART@Home
Description: Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
Study: NCT06483412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Futures: Alternative-to-Suspension Curriculum
Description: Healthy Futures: Alternative-to-Suspension Curriculum uses a trauma-informed and restorative practice lens and uses principles of motivational interviewing (MI) and cognitive-behavioral therapy (CBT) to help students understand the harms of nicotine, reduce stress, increase positive coping, and provide resources to quit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Futures: Alternative-to-Suspension Curriculum
Description: Healthy Futures: Alternative-to-Suspension Curriculum uses a trauma-informed and restorative practice lens and uses principles of motivational interviewing (MI) and cognitive-behavioral therapy (CBT) to help students understand the harms of nicotine, reduce stress, increase positive coping, and provide resources to quit.
Study: NCT06308393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSS0393 ointment；Placebo
Description: RSS0393 ointment；RSS0393 ointment placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSS0393 ointment；Placebo
Description: RSS0393 ointment；RSS0393 ointment placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSS0393 ointment；Placebo
Description: RSS0393 ointment；RSS0393 ointment placebo
Study: NCT04896658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
Description: Study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
Description: Study drug
Study: NCT05135975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
Study: NCT05501444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical antiperspirant
Description: The participants will be instructed to use topical antiperspirant (aluminum chloride, 15 percent every evening for four weeks. The PI will contact the participants every week. If the participant experiences that antiperspirant have an effect, the use of antiperspirant will be reduced from daily use to 3 times a week.
Study: NCT06242925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AbCLO (Abdominal Wall Closure) Device
Description: They will receive the standard of care (Lahey bag covering the bowel, 2 drains in the subcutaneous tissue and Ioban covering everything). The AbClO device has two Rectus Muscle Splints (RMS) to stabilize the rectus abdominis (preventing buckling of these muscles and stabilize the circumferential dynamic retainer (CDR)). The CDR is passed behind the patient's back. The RMSs are positioned on the abdominal wall approximately 2 cm lateral to the wound edges on each side. Additional padding can be applied underneath the RMS. The CDR is passed between the cross bar and the locking strip of each RMS and stretched until taut. The locking strips are locked in position. Four tensioners bridge across the OA from one RMS to the other. Gauze packs should be interposed between the undersurface of the tensioners and the surface of the temporary abdominal coverage to prevent friction. The Tensioners are tightened progressively until complete facial closure.
Study: NCT04971837

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) powder formulation
Description: T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate (Formulation 725: Water soluble.Contains sorbitol)
Study: NCT04936139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: During the 12 planned sessions, different artistic disciplines will be used: visual arts, music, play, narrative, dramatization, movement and body expression.~Each session is structured in 3 phases:~i. A first part of encounter and contextualization, to make contact with oneself, with the art therapist and with the group through a relaxation or meditation activity (35 minutes).~ii. A second part, where the session continues with the work of artistic elaboration and production with the different materials and the different artistic languages (50 minutes).~iii. A third part where the participants will be invited to make a closing, a moment to welcome and share whoever wishes, the experiences that have been experienced. A dialogue is created between Work-Patient-Art Therapist (35 minutes).
Study: NCT05065346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study: NCT04811729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: The participants will apply an approach based on the Motivational Interview (Rollnick, 2008) in patients with excessive alcohol consumption, previously receiving a training program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical advice
Description: Usual care
Study: NCT04950426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: One administration of propranolol, once a week during six weeks. Reading by the participant of his/her traumatic story, 75 minutes (+/- 15 min) after propranolol intake.
Study: NCT04701216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8735
Description: SHR8735 is an thrombopoietin receptor agonist to promote platelet production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8735
Description: SHR8735 is an thrombopoietin receptor agonist to promote platelet production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8735
Description: SHR8735 is an thrombopoietin receptor agonist to promote platelet production.
Study: NCT06166511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Description: Using Laparoscopy in liver resection
Study: NCT05530954

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate (MTA)
Description: Materials for Vital Pulp Capping

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hard setting Calcium Hydroxide (Dycal)
Description: Materials for Vital Pulp Capping
Study: NCT03259698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nPEP
Description: Participants will receive Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25mg (Biktarvy®) one tablet once daily as study drug to complete a 28 day course of PEP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nPEP
Description: Participants will receive Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25mg (Biktarvy®) one tablet once daily as study drug to complete a 28 day course of PEP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nPEP
Description: Participants will receive Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25mg (Biktarvy®) one tablet once daily as study drug to complete a 28 day course of PEP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nPEP
Description: Participants will receive Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25mg (Biktarvy®) one tablet once daily as study drug to complete a 28 day course of PEP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging Support
Description: Text messaging support service ('WelTel'): community-based counselors will provides standardized weekly 'check-in' messages during the participants 12-week course of nPEP follow-up. Participants in the text-message arm will also have the option of receiving generic non-specific automated text reminders of their upcoming appointments in the form of Don't forget about tomorrow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-Led nPEP
Description: nPEP follow-up is provided by nurse-led care at a local sexual health clinic instead of a hospital-based ID physician.
Study: NCT05040178

Intervention type: DRUG
Intervention: Carglumic Acid
Description: Current or previous treatment with Carbaglu, the dose of Carbaglu® prescribed will be determined by the investigator for each individual patient.
Study: NCT05466149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: 240mg QD on a continuous dosing schedule.
Study: NCT05082571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat
Description: Vadadustat tablet orally once a day for 52 weeks
Study: NCT04830748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical knee traction
Description: Continuous knee joint mechanical traction will be applied to the patients positioned in supine lying position with the affected knee flexed at 25-30 degrees by a wedge placed under the affected knee. The thigh will be secured with a strap for stabilization and the leg will be held by the specially designed greave with the weight of traction hanging throughout a pulley system. The amount of traction will be set to about 10% of body weight. The treatment will be applied for 20 minutes continuously, once a day, 3 times per week for 4 weeks. The traction force will be progressed gradually during the program ( e.g.: weekly increase force by 1% of body weight if the patient can tolerate the duration of 20 min with the preset force).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercises
Description: Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force.
Study: NCT04971837

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Oil based tincture formulation
Description: 30 mg CBD isolate in MCT oil,1:1 ratio of CBD to Medium Chain Triglycerides oil. (Formulation 088: Not water soluble. Contains medium chain triglyceride coconut oil.)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation
Description: 10% CBD Gum Arabic, maltodextrin base(Formulation 126: Water soluble. Contains gum arabic and maltodextrin)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Gum Arabic, sorbitol base formulation
Description: 10% CBD Gum Arabic, sorbitol base (Formulation 213: Water soluble. Contains gum arabic and sorbitol)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Isolate in water formulation
Description: Pure CBD as crystalline powder (\>99% purity) (Formulation 625 Not water soluble)
Study: NCT04716595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 ER 0.2 mg/day morning administration (once daily)
Description: K-877 ER 0.2 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 ER 0.2 mg/day evening administration (once daily)
Description: K-877 ER 0.2 mg tablet
Study: NCT04971837

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CBD matching Placebo
Description: Matching Placebo
Study: NCT05368753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Lidocaine blood sample 30 min before the end of the surgery Lidocaine blood sample at the end of the infusion lidocaine and ropivacaine blood sample 2 h after the ropivacaine infusion of the TEA Ropivacaine blood sample 24h after the infusion of the TEA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end) The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end), then ropivacaine will be injected in the TEA at the same time and infused during 24h. The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.
Study: NCT05706415

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinicians will review the suggestions of a hypothetical AI
Description: There is no intervention. Clinicians will review the suggestions of a hypothetical AI
Study: NCT06152263

Intervention type: OTHER
Intervention: Compare color information and mucosal microvascular density
Description: To investigate the association between the color and mucosal microvascular density of CAG and EGC using linked color imaging.
Study: NCT05388071

Intervention type: OTHER
Intervention: Usage of telemedicine and tele-consultation for treatment
Description: Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.